Latest Conference Articles

Whether administered as an immune primer or concurrently with extended field chemoradiation, atezolizumab demonstrated efficacy in triggering T-cell clonal expansions and prolonging progression-free survival in patients with cervical cancer.

Selinexor demonstrated impressive efficacy in extending progression-free survival among patient with advanced or recurrent endometrial cancer, particularly among patients with wild-type p53 endometrial cancer.

The ongoing FLORA-5 trial will assess whether the addition of oregovomab to a standard chemotherapy regimen will improve progression-free and overall survival in patients with advanced epithelial ovarian cancer.

La-Urshala Brock, FNP-BC, CNM, RNFA, discusses effective toxicity management for patients with breast cancer receiving pembrolizumab.

As prognoses continue to improve, concerns about treatment-associated fertility risks are becoming more prevalent and are often a topic of discussion between patients and their nurses or nurse practitioners.

Patients with metastatic renal cell carcinoma have multiple effective frontline treatment options.

A Yale Cancer Center expert offers a quick glance at the metastatic urothelial cancer treatment landscape.

Charles L. Loprinzi, MD, discusses the efficacy of agents like gabapentin and olanzapine to combat breast cancer treatment-related pains and speaks to the future of nonestrogenic toxicity management within this space.

Lindsay Kroener, MD, offers an overview of current fertility preservation options for patients about to undergo cancer therapy.

Frontline treatment with poziotinib yielded promising overall response rates in patients with non–small cell lung cancer and HER2 exon 20 insertion mutations.

Ahead of his presentation at the 39th Annual Miami Breast Cancer Conference, Charles L. Loprinzi, MD, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer.

At a presentation during the 39th Annual Miami Breast Cancer Conference, Lindsay Kroener, MD, highlighted key components related to fertility preservation for patients with breast cancer.

Real-world findings presented at the 39th Annual Miami Breast Cancer Conference showed that eribulin may be an effective agent for previously treated patients with metastatic breast cancer.

The nurse-specific track returns to the Miami Breast Cancer Conference® agenda for a second year in 2022.

Preliminary findings suggest that enfortumab vedotin may be an effective treatment option for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Adjuvant mitotane did not yield a significantly reduced risk of recurrence among patients with adrenocortical carcinoma.

The immunotherapy combination of nivolumab and ipilimumab elicited favorable health-related quality of life responses compared with sunitinib in patients with advanced renal cell carcinoma.

Cabozantinib is determined to be a safe treatment option for patients with metastatic renal cell carcinoma whose disease failed to respond to prior immunotherapy combinations.

Patients with 4-1BB or LAG-3–expressing T cells at baseline, or a high proportion of PD-L1–expressing myeloid cells and plasmacytoid dendritic cells during boost cycles, may be more likely to benefit from the combination of nivolumab and ipilimumab.

Adding sacituzumab govitecan to second-line pembrolizumab garnered promising antitumor activity among patients with checkpoint inhibitor–naïve metastatic urothelial cancer.

Nivolumab plus cabozantinib outperformed sunitinib in maintaining health-related quality of life in patients with advanced renal cell carcinoma.

A post-hoc analysis of 2 studies revealed that patients with advanced prostate cancer receiving apalutamide reported positive wellbeing scores during treatment.

The androgen receptor inhibitor darolutamide prolonged overall survival compared with placebo in patients with at least 6 comorbidities.

Frontline niraparib, abiraterone acetate, and prednisone yielded improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.

First-line treatment with olaparib plus abiraterone resulted in a 34% risk reduction of radiographic disease progression or death in patients with metastatic castration-resistant prostate cancer.

Combination therapy, selective estrogen receptor degraders, and more were covered at the 2021 San Antonio Breast Cancer Symposium.

Oral Bruton tyrosine kinase inhibitors make notable strides in CLL treatment. Chimeric antigen receptor T-cell therapy continues to command attention by besting standard-of-care therapies.

The oral targeted therapy was linked with maintained appetite, eating habits, and physical function in patients with IDH1-mutated cholangiocarcinoma.